Allergy Therapeutics Sustainability Profile
Allergy Therapeutics, a leading specialist in allergy immunotherapy, is headquartered in the United Kingdom and operates extensively across Europe and North America. Founded in 2003, the company has established itself as a pioneer in the development of innovative allergy treatments, focusing on both the diagnosis and management of allergic conditions. The firm’s core offerings include a range of allergy vaccines and immunotherapy products, distinguished by their unique formulations and patient-centric approach. Allergy Therapeutics is committed to advancing the field of allergy treatment, evidenced by its robust pipeline and significant clinical milestones. With a strong market position, the company continues to make strides in improving patient outcomes and enhancing the quality of life for those affected by allergies.
DitchCarbon Score
How does Allergy Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Allergy Therapeutics's score of 37 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Allergy Therapeutics's reported carbon emissions
In 2024, Allergy Therapeutics reported total carbon emissions of approximately 2,687,000 kg CO2e. This figure reflects a significant decrease from 2023, when emissions were about 4,291,000 kg CO2e, comprising 431,000 kg CO2e from Scope 1, 1,901,000 kg CO2e from Scope 2, and 1,959,000 kg CO2e from Scope 3 emissions. In 2022, the company recorded total emissions of around 4,040,000 kg CO2e, with similar scope breakdowns: 437,000 kg CO2e (Scope 1), 1,742,000 kg CO2e (Scope 2), and 1,861,000 kg CO2e (Scope 3). The 2021 emissions were reported at about 3,017,000 kg CO2e, with Scope 1 emissions of 129,000 kg CO2e and Scope 2 emissions of 1,965,000 kg CO2e, while Scope 3 emissions from business travel accounted for 614,000 kg CO2e. Data for 2020 is not available, indicating a lack of emissions reporting for that year. Despite the fluctuations in emissions, Allergy Therapeutics has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or SBTi commitments. The company’s emissions data is not cascaded from any parent organization, ensuring that the reported figures are solely from Allergy Therapeutics plc. Overall, Allergy Therapeutics is actively monitoring its carbon footprint, with a notable reduction in emissions from 2023 to 2024, but further commitments and strategies for long-term sustainability remain unspecified.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 129,000 | 000,000 | 000,000 |
| Scope 2 | 2,273,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 614,000 | 0,000,000 | 0,000,000 |
How Carbon Intensive is Allergy Therapeutics's Industry?
How Carbon Intensive is Allergy Therapeutics's Location?
Allergy Therapeutics's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Allergy Therapeutics has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
